Repository logo
 
Publication

Effect of empagliflozin beyond glycemic control: Cardiovascular benefit in patients with type 2 diabetes and established cardiovascular disease

2019-12-28Journal article Open access
Simple item page
dc.contributor.authorMonteiro, P
dc.contributor.authorAguiar, C
dc.contributor.authorMatos, P
dc.contributor.authorSilva-Nunes, J
dc.contributor.authorBirne, R
dc.contributor.authorBranco, P
dc.contributor.authorCalado, J
dc.contributor.authorMelo, M
dc.contributor.authorPolónia, J
dc.date.accessioned2020-01-15T23:28:56Z
dc.date.available2020-01-15T23:28:56Z
dc.date.issued2019-12-28
dc.description.abstractThe prevalence of type 2 diabetes (T2D) continues to increase, and its association with cardiovascular (CV) disease has led to the inclusion of CV endpoints in clinical trials on the treatment of T2D. This article explores the various trials already performed and under development in this field, with particular focus on the EMPA-REG OUTCOME trial. In this trial, empagliflozin, a sodium-glucose co-transporter 2 inhibitor, demonstrated a reduction in CV risk in patients with T2D and established CV disease, in addition to CV safety and a decrease in glycated hemoglobin. This represents a paradigm shift that has led to changes in the international guidelines for the treatment of T2D. These results were maintained in subsequent subgroup analysis for heart failure, chronic kidney disease and peripheral arterial disease, although there are many questions concerning the mechanisms involved in these effects, including whether they are hemodynamic, metabolic or due to decreased myocardial cytoplasmic sodium concentrations. With this reduction in risk for major CV events in patients with T2D, the EMPA-REG OUTCOME trial demonstrated CV protection from a hypoglycemic drug for the first time, and opened a new era in the treatment and management of T2D. This study has led to the development of ongoing trials that will establish which patients will benefit most from this therapy, particularly with regard to comorbidities.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationRev Port Cardiol. 2019 Dec 28. pii: S0870-2551(19)30480-9.pt_PT
dc.identifier.doi10.1016/j.repc.2019.02.008pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.26/30991
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.subjectDoenças Cardiovascularespt_PT
dc.subjectDiabetes Mellitus Tipo 2pt_PT
dc.subjectEmpagliflozinapt_PT
dc.subjectCardiovascular Diseasespt_PT
dc.subjectDiabetes Mellitus, Type 2pt_PT
dc.subjectEmpagliflozinpt_PT
dc.titleEffect of empagliflozin beyond glycemic control: Cardiovascular benefit in patients with type 2 diabetes and established cardiovascular diseasept_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.titleRevista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiologypt_PT
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Rev Port Cardiol. 2019.pdf
Size:
1.44 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.85 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Saúde - CUF - Infante Santo - Artigos Científicos